Status:
COMPLETED
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Chronic Kidney Disease Requiring Hemodialysis
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.
Eligibility Criteria
Inclusion
- Patients age 20 or older, regardless of gender.
- Receiving stable maintenance hemodialysis 3 times a week.
- Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.
Exclusion
- Patients having history of a pronounced brain / cardiovascular disorder.
- Patients having severe gastrointestinal disorders.
- Patients having severe hepatic disorders.
Key Trial Info
Start Date :
January 11 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2012
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT01521494
Start Date
January 11 2012
End Date
July 3 2012
Last Update
August 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Japan
Multiple Locations, Japan